Earnings Call Summary | Trevi Therapeutics(TRVI.US) Q4 2023 Earnings Conference
Earnings Call Summary | Trevi Therapeutics(TRVI.US) Q4 2023 Earnings Conference
The following is a summary of the Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript:
以下是特雷維療法公司（TRVI）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
No financial performance details provided for this period.
沒有提供該期間的財務業績詳情。
Business Progress:
業務進展：
Trevi initiated three clinical trials towards the end of 2023.
Trevi is progressing with the Phase 2a RIVER trial for Refractory Chronic Cough, a condition currently lacking approved therapeutic solutions.
The drug under test, Haduvio, shows potential for treating patients across different cough frequencies.
A Phase 2b study for chronic cough in IPS was also initiated at the end of 2023.
Progress is seen in the Human Abuse Potential (HAP) study, with more than half the target demographic already enrolled.
Topline data from the chronic cough and HAP studies are anticipated to be released in the second half of this year.
Significant updates are anticipated after end-of-Phase 2 meetings are initiated.
特雷維在2023年底啓動了三項臨床試驗。
特雷維正在進行鍼對難治性慢性咳嗽的2a期RIVER試驗，該病目前缺乏經批准的治療解決方案。
正在測試的藥物Haduvio顯示出治療不同咳嗽頻率患者的潛力。
一項針對IPS慢性咳嗽的2b期研究也於2023年底啓動。
潛在人類虐待（HAP）研究取得了進展，超過一半的目標人群已經入學。
慢性咳嗽和HAP研究的主要數據預計將在今年下半年發佈。
預計在第二階段結束會議啓動後，將進行重大更新。
More details: Trevi Therapeutics IR
更多詳情： 特雷維療法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。